Fundraising Fox

Eterna Therapeutics

NASDAQ: ERNA

Cambridge, US · Founded 1994 · Delaware corporation · 8 employees on LinkedIn

Biotech

Founders & leadership

DC
Dorothy ClarkeinExecutive
SG
Sandra GurrolainExecutive
SL
Sanjeev LutherinExecutive
KD
Kevin D'AmourinChief Scientific Officer
RS
Roger SidhuinChief Medical Officer
HJ
Howard J. FederoffinChief Executive Officer and President
JS
Jay SialinChief Administration Officer
ES
Erin S. EnrightNamed on SEC filing
EM
Erich MohrNamed on SEC filing
CC
Charles CheringtonNamed on SEC filing
DL
Dennis LangerNamed on SEC filing
HB
Heather B. RedmanNamed on SEC filing

Reported raises · per SEC filings

Form D private placements

$57.2M disclosed across 8 rounds · 2022–2025

▶$7.2MraisedApr 2025 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Peter CicalaDirector
  • Sandra GurrolaExecutive Officer
  • William WexlerDirector
  • James BristolDirector
  • Sanjeev LutherExecutive Officer, Director
  • Elena RatnerDirector
Offering amount
$7.2M
Amount sold
$7.2M
First sale
Mar 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.1MraisedNov 2024 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Dorothy ClarkeExecutive Officer, Director
  • Sanjeev LutherExecutive Officer, Director
  • William WexlerDirector
  • Sandra GurrolaExecutive Officer
  • James BristolDirector
  • Peter CicalaDirector
Offering amount
$1.1M
Amount sold
$1.1M
First sale
Sep 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.9MraisedNov 2024 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Dorothy ClarkeExecutive Officer, Director
  • William WexlerDirector
  • Sandra GurrolaExecutive Officer
  • Sanjeev LutherExecutive Officer, Director
  • James BristolDirector
  • Peter CicalaDirector
Offering amount
$3.9M
Amount sold
$3.9M
First sale
Sep 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7.8MraisedDec 2023 · 19 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • James BristolDirector
  • William WexlerDirector
  • Matthew AngelExecutive Officer
  • Dorothy ClarkeDirector
  • Sandra GurrolaExecutive Officer
Offering amount
$9.2M
Amount sold
$7.8M
First sale
Dec 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8.7MraisedJul 2023 · 19 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Sandra GurrolaExecutive Officer
  • Brant BinderDirector
  • Richard W. WagnerDirector
  • Gregory FioreDirector
  • Matthew AngelExecutive Officer, Director
  • William WexlerDirector
Offering amount
$8.7M
Amount sold
$8.7M
First sale
Jul 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8.7MraisedJul 2023 · 19 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Matthew AngelExecutive Officer, Director
  • Gregory FioreDirector
  • Brant BinderDirector
  • Richard W. WagnerDirector
  • William WexlerDirector
  • Sandra GurrolaExecutive Officer
Offering amount
$8.7M
Amount sold
$8.7M
First sale
Jul 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7.7MraisedDec 2022 · 20 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Andrew JacksonExecutive Officer
  • William WexlerDirector
  • Matthew AngelDirector, Executive Officer
  • Gregory FioreDirector
  • Nicholas J. SingerDirector
  • Charles CheringtonDirector
  • Sandra GurrolaExecutive Officer
  • Roger SidhuExecutive Officer
Offering amount
$7.7M
Amount sold
$7.7M
First sale
Dec 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$12MraisedMar 2022 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Sandra GurrolaExecutive Officer
  • Erin S. EnrightDirector
  • Kevin D'AmourExecutive Officer
  • Roger SidhuExecutive Officer
  • Erich MohrDirector
  • Charles CheringtonDirector
  • Howard J. FederoffExecutive Officer, Director
  • Jay SialExecutive Officer
  • Dennis LangerDirector
  • Heather B. RedmanDirector
Offering amount
$12M
Amount sold
$12M
Sales commissions
$900K
Placement agents
Cantor Fitzgerald & Co., Maxim Group LLC
First sale
Mar 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Eterna Therapeutics Updates Investor Presentation, Highlights Web Disclosures - TipRanks.comtipranks.com · Jul 2026Eterna Therapeutics Earnings 2025 Annual | ERNA News & Analysispanabee.com · Mar 2026Eterna Therapeutics Inc. announced that it has received $0.75 million in funding | MarketScreenermarketscreener.com · Mar 2025Eterna Therapeutics faces Nasdaq delisting over market value By Investing.cominvesting.com · Jan 2025Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success - BioSpacebiospace.com · Oct 2024

Frequently asked questions

How much funding has Eterna Therapeutics raised?
Eterna Therapeutics has disclosed $57.2M raised across 8 rounds.
Where is Eterna Therapeutics headquartered?
Eterna Therapeutics is headquartered in Cambridge, US.